Anna Zoccarato1, Nicoletta C Surdo1, Jan M Aronsen1, Laura A Fields1, Luisa Mancuso1, Giuliano Dodoni1, Alessandra Stangherlin1, Craig Livie1, He Jiang1, Yuan Yan Sin1, Frank Gesellchen1, Anna Terrin1, George S Baillie1, Stuart A Nicklin1, Delyth Graham1, Nicolas Szabo-Fresnais1, Judith Krall1, Fabrice Vandeput1, Matthew Movsesian1, Leonardo Furlan1, Veronica Corsetti1, Graham Hamilton1, Konstantinos Lefkimmiatis1, Ivar Sjaastad1, Manuela Zaccolo2. 1. From the Institute of Neuroscience and Psychology (A.Z., L.A.F., A.S., C.L., H.J., F.G., A.T., G.H., M.Z.) and Institute of Cardiovascular and Medical Sciences (Y.Y.S., G.S.B., S.A.N., D.G.), University of Glasgow, Glasgow, UK; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK (N.C.S., K.L., M.Z.); Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway (J.M.A., I.S.); Venetian Institute of Molecular Medicine, University of Padova, Padova, Italy (L.M., G.D., A.T., L.F., V.C.); Cardiology Section, VA Salt Lake City Health Care System and Cardiovascular Medicine Division, University of Utah School of Medicine, Salt Lake City, UT (N.S.-F., J.K., F.V., M.M.); Bjorknes College, Oslo, Norway (J.M.A.); and BHF Centre of Research Excellence, Oxford, UK (K.L., M.Z.). 2. From the Institute of Neuroscience and Psychology (A.Z., L.A.F., A.S., C.L., H.J., F.G., A.T., G.H., M.Z.) and Institute of Cardiovascular and Medical Sciences (Y.Y.S., G.S.B., S.A.N., D.G.), University of Glasgow, Glasgow, UK; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK (N.C.S., K.L., M.Z.); Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway (J.M.A., I.S.); Venetian Institute of Molecular Medicine, University of Padova, Padova, Italy (L.M., G.D., A.T., L.F., V.C.); Cardiology Section, VA Salt Lake City Health Care System and Cardiovascular Medicine Division, University of Utah School of Medicine, Salt Lake City, UT (N.S.-F., J.K., F.V., M.M.); Bjorknes College, Oslo, Norway (J.M.A.); and BHF Centre of Research Excellence, Oxford, UK (K.L., M.Z.). manuela.zaccolo@dpag.ox.ac.uk.
Abstract
RATIONALE: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodeling and cardiac hypertrophy. However, enhancement of particular aspects of cAMP/protein kinase A signaling seems to be beneficial for the failing heart. cAMP is a pleiotropic second messenger with the ability to generate multiple functional outcomes in response to different extracellular stimuli with strict fidelity, a feature that relies on the spatial segregation of the cAMP pathway components in signaling microdomains. OBJECTIVE: How individual cAMP microdomains affect cardiac pathophysiology remains largely to be established. The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in shaping local changes in cAMP. Here we investigated the effect of specific inhibition of selected PDEs on cardiac myocyte hypertrophic growth. METHODS AND RESULTS: Using pharmacological and genetic manipulation of PDE activity, we found that the rise in cAMP resulting from inhibition of PDE3 and PDE4 induces hypertrophy, whereas increasing cAMP levels via PDE2 inhibition is antihypertrophic. By real-time imaging of cAMP levels in intact myocytes and selective displacement of protein kinase A isoforms, we demonstrate that the antihypertrophic effect of PDE2 inhibition involves the generation of a local pool of cAMP and activation of a protein kinase A type II subset, leading to phosphorylation of the nuclear factor of activated T cells. CONCLUSIONS: Different cAMP pools have opposing effects on cardiac myocyte cell size. PDE2 emerges as a novel key regulator of cardiac hypertrophy in vitro and in vivo, and its inhibition may have therapeutic applications.
RATIONALE: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodeling and cardiac hypertrophy. However, enhancement of particular aspects of cAMP/protein kinase A signaling seems to be beneficial for the failing heart. cAMP is a pleiotropic second messenger with the ability to generate multiple functional outcomes in response to different extracellular stimuli with strict fidelity, a feature that relies on the spatial segregation of the cAMP pathway components in signaling microdomains. OBJECTIVE: How individual cAMP microdomains affect cardiac pathophysiology remains largely to be established. The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in shaping local changes in cAMP. Here we investigated the effect of specific inhibition of selected PDEs on cardiac myocyte hypertrophic growth. METHODS AND RESULTS: Using pharmacological and genetic manipulation of PDE activity, we found that the rise in cAMP resulting from inhibition of PDE3 and PDE4 induces hypertrophy, whereas increasing cAMP levels via PDE2 inhibition is antihypertrophic. By real-time imaging of cAMP levels in intact myocytes and selective displacement of protein kinase A isoforms, we demonstrate that the antihypertrophic effect of PDE2 inhibition involves the generation of a local pool of cAMP and activation of a protein kinase A type II subset, leading to phosphorylation of the nuclear factor of activated T cells. CONCLUSIONS: Different cAMP pools have opposing effects on cardiac myocyte cell size. PDE2 emerges as a novel key regulator of cardiac hypertrophy in vitro and in vivo, and its inhibition may have therapeutic applications.
Authors: Madeline Nieves-Cintrón; Dinesh Hirenallur-Shanthappa; Patrick J Nygren; Simon A Hinke; Mark L Dell'Acqua; Lorene K Langeberg; Manuel Navedo; Luis F Santana; John D Scott Journal: Cell Signal Date: 2015-12-24 Impact factor: 4.315
Authors: Si Chen; Yishuai Zhang; Janet K Lighthouse; Deanne M Mickelsen; Jiangbin Wu; Peng Yao; Eric M Small; Chen Yan Journal: Circulation Date: 2019-12-05 Impact factor: 29.690
Authors: Giulia Vigone; Leia C Shuhaibar; Jeremy R Egbert; Tracy F Uliasz; Matthew A Movsesian; Laurinda A Jaffe Journal: Endocrinology Date: 2018-05-01 Impact factor: 4.736